| Market Cap | 69.35M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -17.55M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 15.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -4.00% |
| Dividend | N/A | Price/Book | 5.20 | EPS next 5Y | - | 52W High Chg | -72.00% |
| Recommedations | - | Quick Ratio | 0.44 | Shares Outstanding | 2.37M | 52W Low Chg | 113.00% |
| Insider Own | 6.61% | ROA | -50.46% | Shares Float | 2.11M | Beta | 2.69 |
| Inst Own | 6.62% | ROE | -101.36% | Shares Shorted/Prior | 263.63K/321.75K | Price | 1.70 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 679,187 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 1,298,762 | Change | 1.80% |
MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. The company was founded in 2014 and is headquartered in Baltimore, Maryland.